FDA approves drug to treat 2 types of AMLAugust 4, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
FDA approves enasidenib to treat relapsed/refractory AMLAugust 2, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
FDA grants drug breakthrough designation for AMLJuly 30, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Predicting response to treatment in AML, MDSJuly 26, 2017AnemiaLeukemia, Myelodysplasia, TransplantationAMLMyelodysplastic Syndrome
CHMP recommends midostaurin for FLT3+ AML, SMJuly 23, 2017Leukemia, Myelodysplasia, TransplantationAML
FDA grants orphan designation to gilteritinib in AMLJuly 21, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Combo may be option for elderly patients with untreated AMLJuly 19, 2017Leukemia, Myelodysplasia, TransplantationAML
Benefits of gemtuzumab ozogamicin outweigh risks, ODAC saysJuly 13, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Company discontinues phase 3 trial of vadastuximab talirine in AMLJune 20, 2017Leukemia, Myelodysplasia, TransplantationAMLMyelodysplastic Syndrome
‘Admirable’ overall survival attainable in AML with enasidenibJune 16, 2017Leukemia, Myelodysplasia, TransplantationAML
Deep molecular responses achievable in AML pts treated with gilteritinibJune 12, 2017Leukemia, Myelodysplasia, TransplantationAML
Majority of AML patients do not receive recommended molecular genetic testingJune 11, 2017Leukemia, Myelodysplasia, TransplantationAML
Differences emerge in new guidelines for managing FN in kidsJune 3, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsTransplantationAMLALLAggressive Lymphomas
EC grants drug orphan designation for AMLMay 26, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
